TTrialPathMatch Me to Trials
← Back to trials
RecruitingErythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)EPP2

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

Eligible age

12+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: Part 1: Phase 2b * Find the right dose of PORT-77 to lower PPIX levels in the blood * Test if PORT-77 lowers PPIX levels better than placebo * Check the safety of each dose Part 2: Phase 3 * Test if PORT-77 lowers PPIX levels better than placebo * Test if PORT-77 increases the amount of time patients spend in sunlight each day without pain compared to placebo * Check the safety of PORT-77 Part 3: Open-Label Extension (OLE) * Test the long-term effect of PORT-77 on PPIX levels and time in sun * Monitor long-term safety

Sponsor: Portal Therapeutics, Inc.

You may qualify if…

  • ✓ Aged 12 years or older.
  • ✓ Clinical history of EPP, XLP, or EPP2 supported by genetic confirmation or historical laboratory test results
  • ✓ History of consistent, non-painful prodrome within approximately 45 minutes of sunlight exposure and prior to phototoxic attacks
  • ✓ Demonstrates ≥85% compliance with daily symptom diary during run-in period.
  • ✓ Body weight or BMI at Screening as follows:
  • ✓ 1. For participants aged 12 to \<18 years: body weight ≥32 kg
  • ✓ 2. For participants aged ≥18 years: BMI ≥18.5 kg/m2
  • ✓ AST and ALT \<3 × ULN and total bilirubin \<2 × ULN (unless documented Gilbert syndrome) at Screening

You may not qualify if…

  • ✕ Diagnosis of another porphyria or another photodermatosis that may confound the evaluation of PORT-77
  • ✕ Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory assessments
  • ✕ Major surgery within 8 weeks before Screening, incomplete recovery from any previous surgery, or major surgery planned to occur during the study
  • ✕ History of, or anticipated need for, liver transplantation or history of bone marrow transplantation
  • ✕ Active infection with hepatitis B or C
  • ✕ Unable to swallow tablets or has a disease that significantly affects gastrointestinal function
  • ✕ Any other disease, condition, or circumstance that, at the discretion of the Investigator or Sponsor, would interfere with the evaluation of PORT-77 or study participation, or would make study participation not in the best interest of the participant
  • ✕ History of drug or alcohol abuse within the last 12 months, or current or planned use of prohibited or illegal substances

Where it's recruiting

California

Huntington Beach

Ohio

Cincinnati

Source: ClinicalTrials.gov · NCT07820085 · last updated 2026-09-15

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Pa · TrialPath